| Lung Cancer |
1 |
0.8 |
| Cancer |
0 |
0.9 |
| Cancer Risk |
0 |
0.73 |
| Renal Cell Carcinoma |
0 |
0.67 |
| Hypertension |
0 |
0.62 |
| Meta-Analysis |
0 |
0.26 |
| Food and Drug Administration (FDA) |
0 |
0.23 |
| Lung |
0 |
0.18 |
| Antihypertensive Agents |
0 |
0.09 |
| ACE Inhibitor |
0 |
0.07 |
| Angiotensin II Receptor Blockade |
0 |
0.07 |
| Cardiovascular Risk Management |
0 |
0.06 |
| Receptors |
0 |
0.05 |
| Cardiovascular disease |
0 |
0.04 |
| Clinical Guidelines |
0 |
0.04 |
| Geriatrics |
0 |
0.04 |
| Arrhythmia |
0 |
0.03 |
| Calcium Channel Blockers |
0 |
0.03 |
| Renal Disease |
0 |
0.03 |
| Adherence |
0 |
0.02 |
| Adverse Effects |
0 |
0.02 |
| Board Certification |
0 |
0.02 |
| Calcium |
0 |
0.02 |
| Carcinogen |
0 |
0.02 |
| Cerebrovascular Accident |
0 |
0.02 |
| Clinical Research |
0 |
0.02 |
| Face |
0 |
0.02 |
| Kidney |
0 |
0.02 |
| Osteoarthritis |
0 |
0.02 |
| Patient Safety |
0 |
0.02 |
| Statistics |
0 |
0.02 |
| Stress |
0 |
0.02 |